Cytek Biosciences IncNASDAQ:CTKB
- LAST PRICE6.5100
- TODAY'S CHANGE (%)-0.1800 (-2.6906%)
- Bid / Lots6.5000/ 3
- Ask / Lots6.5200/ 8
- Open / Previous Close6.6000 / 6.6900
- Day Range
- 52 Week Range
- Volume168,376
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | CTKB |
|---|---|---|
| 09:32 ET | 15034 | 6.43 |
| 09:33 ET | 3196 | 6.55 |
| 09:35 ET | 1021 | 6.52 |
| 09:37 ET | 2504 | 6.57 |
| 09:39 ET | 1200 | 6.59 |
| 09:42 ET | 1376 | 6.52 |
| 09:44 ET | 3596 | 6.53 |
| 09:46 ET | 500 | 6.53 |
| 09:48 ET | 1132 | 6.545 |
| 09:50 ET | 28536 | 6.42 |
| 09:51 ET | 100 | 6.43 |
| 09:53 ET | 200 | 6.415 |
| 09:55 ET | 1263 | 6.42 |
| 10:00 ET | 400 | 6.42 |
| 10:02 ET | 56658 | 6.52 |
| 10:04 ET | 4352 | 6.54 |
| 10:06 ET | 2851 | 6.49 |
| 10:08 ET | 1088 | 6.5 |
| 10:09 ET | 500 | 6.52 |
| 10:11 ET | 3823 | 6.455 |
| 10:13 ET | 700 | 6.45 |
| 10:15 ET | 300 | 6.455 |
| 10:18 ET | 500 | 6.455 |
| 10:20 ET | 500 | 6.46 |
| 10:22 ET | 2608 | 6.45 |
| 10:24 ET | 1600 | 6.48 |
| 10:26 ET | 1542 | 6.46 |
| 10:27 ET | 662 | 6.455 |
| 10:29 ET | 2030 | 6.51 |
Nov 20, 2024
Cytek Biosciences to participate in the Piper Sandler 36th Annual Healthcare Conference, from 4:06PM ET on Wednesday Nov 20, 2024 by Dow Jones
4:06PM ET on Wednesday Nov 20, 2024 by Dow Jones
Nov 19, 2024
Cytek(R) Biosciences Named "Overall BioTech Company of the Year" in 2024 BioTech Breakthrough Awards Program, from 5:00PM ET on Tuesday Nov 19, 2024 by Dow Jones
5:00PM ET on Tuesday Nov 19, 2024 by Dow Jones
Nov 11, 2024
DJ Cytek Biosciences Is Maintained at Overweight by Piper Sandler, from 8:01AM ET on Monday Nov 11, 2024 by Dow Jones
8:01AM ET on Monday Nov 11, 2024 by Dow Jones
Nov 7, 2024
Cytek(R) Biosciences Becomes First Company to Add Ability to Detect Subcellular Particles to Its Cell Sorter, from 5:00PM ET on Thursday Nov 07, 2024 by Dow Jones
5:00PM ET on Thursday Nov 07, 2024 by Dow Jones
Nov 5, 2024
Press Release: Cytek Biosciences Reports Third Quarter 2024 Financial Results, from 4:05PM ET on Tuesday Nov 05, 2024 by Dow Jones
4:05PM ET on Tuesday Nov 05, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Cytek Biosciences Inc | 843.7M | -83.2x | --- |
Pacific Biosciences of California Inc | 493.0M | -1.2x | --- |
AxoGen Inc | 587.1M | -41.0x | --- |
Zynex Inc | 263.0M | 56.1x | +1.09% |
Standard BioTools Inc | 595.6M | -2.2x | --- |
Quanterix Corp | 451.0M | -11.7x | --- |
Company Information
Cytek Biosciences, Inc. is a cell analysis solutions company. The Company is advancing the cell analysis tools by delivering high-resolution, high-content and high-sensitivity cell analysis utilizing its Full Spectrum Profiling (FSP) technology. Its FSP platform includes its core instruments, the Cytek Aurora and Northern Lights systems; its cell sorter, the Cytek Aurora CS; the Cytek Orion reagent cocktail preparation system; the flow cytometer and imaging products under the Amnis and Guava brands; and reagents, software and services to provide a comprehensive and integrated suite of solutions for its customers. Its Cytek Aurora and Cytek Northern Lights systems are flow cytometers that deliver high-resolution, high-content, and high-sensitivity cell analysis. Its Cytek Aurora CS is a cell sorter that leverages the detection and sensitivity capabilities of its FSP technology to isolate living cell populations from lower to higher complexity panels beyond 40 biomarkers.
Contact Information
- Headquarters
- 47215 LAKEVIEW BOULEVARDFREMONT, CA, United States 94538
- Phone
- ---
- Fax
- ---
Executives
- Chairman of the Board, President, Chief Executive Officer, Co-Founder
- Wenbin Jiang
- Co-Founder, Chief Technology Officer, Director
- Ming Yan
- Chief Financial Officer
- William Mccombe
- Senior Vice President, Global Sales and Services
- Philippe Busque
- Senior Vice President - Business & Corporate Development
- Allen Poirson
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $843.7M |
|---|---|
Revenue (TTM) | $201.2M |
Shares Outstanding | 128.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.46 |
EPS | $-0.08 |
Book Value | $3.01 |
P/E Ratio | -83.2x |
Price/Sales (TTM) | 4.2 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -11.75% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
